Shen-zhi-ling oral liquid improves behavioral and psychological symptoms of dementia in Alzheimer's disease.

Shen-zhi-ling oral liquid improves behavioral and psychological symptoms of dementia in Alzheimer's disease.
复制标题

DOI:
10.1155/2014/913687
复制
发表时间:
2014
期刊:
Evidence-based complementary and alternative medicine : eCAM
影响因子:
--
通讯作者:
Yamamoto Y
Yamamoto Y
中科院分区:
其他
文献类型:
--
作者:
Pan W;Wang Q;Kwak S;Song Y;Qin B;Wang M;Yamamoto Y

文献摘要

参考文献

被引文献

相似文献

我们评价了中药参智灵口服液(SZL)对阿尔茨海默病(AD)患者痴呆行为和心理症状(BPSD)的影响。在入组的98例AD和BPSD患者(平均年龄,57.2 ± 8.9岁)中,91例(M = 55,F = 36;平均年龄,57.2 ± 9.7岁)完成了研究。患者以双盲方式服用SZL(n = 45)或安慰剂颗粒(n = 46)20周,同时维持其他抗认知药物不变。采用阿尔茨海默病行为病理学(SDE VE-AD)评定量表和神经精神量表(NPI)评估第0周、第10周、第20周和第25周之间BPSD的变化,根据活动记录仪记录,以日间活动(DA)、夜间活动(EA)和夜间活动(NA)为代表进行去趋势波动分析(DFA)。与0周相比,SZL口服液而不是安慰剂口服液显著延迟BPSD的发展,这与20周时DFA的部分临床评分和EA和NA参数的变化有关。在实验室检查中未观察到副作用。结果表明,SZL可能延缓AD患者BPSD的发展,因此是一种潜在的长期使用的合适药物。
We evaluated the effects of the traditional Chinese medicine (TCM) Shen-Zhi-Ling oral liquid (SZL) on the behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer's disease (AD). Among 98 patients with AD and BPSD enrolled (mean age, 57.2 ± 8.9 years old), 91 (M = 55, F = 36; mean age, 57.2 ± 9.7 years old) completed the study. Patients took either SZL (n = 45) or placebo granules (n = 46) in a double-blind manner for 20 weeks while maintaining other anticognitive medications unchanged. Changes in BPSD between week 0, week 10, week 20, and week 25 were assessed using the behavioral pathology in Alzheimer's disease (BEHAVE-AD) rating scale and the neuropsychiatric inventory (NPI), detrended fluctuation analysis (DFA) represented by diurnal activity (DA), evening activity (EA), and nocturnal activity (NA) according to actigraphic recordings. SZL but not placebo oral liquid delayed the development of BPSD significantly according to the changes in some of the clinical scores and the EA and NA parameters of DFA at week 20 compared with week 0. No side effects were observed in laboratory tests. The results indicate that SZL might delay the development of BPSD in AD patients and thus is a potentially suitable drug for long-term use.
DOI: 10.4061/2011/789506
发表时间: 2011
期刊: Parkinson's disease
影响因子: --
作者:
Pan W;Kwak S;Liu Y;Sun Y;Fang Z;Qin B;Yamamoto Y
通讯作者: Yamamoto Y
DOI: 10.1345/aph.1k372
发表时间: 2008-01-01
影响因子: 2.9
作者:
Maidment, Ian D.;Fox, Chris G.;Katona, Cornelius L.
通讯作者: Katona, Cornelius L.
DOI: 10.1002/mds.21527
发表时间: 2007-07-15
期刊: MOVEMENT DISORDERS
影响因子: 8.6
作者:
Pan, Weidong;Ohashi, Kyoko;Kwak, Shin
通讯作者: Kwak, Shin
DOI: 10.1016/j.jalz.2012.12.002
发表时间: 2013-11-01
影响因子: 14
作者:
Obermann, Karen R.;Morris, John C.;Roe, Catherine M.
通讯作者: Roe, Catherine M.
DOI: 10.1155/2013/613596
发表时间: 2013
期刊: Evidence-based complementary and alternative medicine : eCAM
影响因子: --
作者:
Pan W;Chen X;Bao J;Bai Y;Lu H;Wang Q;Liu Y;Yuan C;Li W;Liu Z;Liu J;Zhu X;Qin B;Cai D;Zhou H
通讯作者: Zhou H